RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+19.56%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$940M
AUM Growth
+$940M
(-11%)
Cap. Flow
-$249M
Cap. Flow
% of AUM
-26.46%
Top 10 Holdings %
Top 10 Hldgs %
62.65%
Holding
57
New
1
Increased
–
Reduced
32
Closed
9
Top Buys
| 1 |
HNGE
Hinge Health, Inc.
HNGE
|
$15.5M |
Top Sells
| 1 |
Amicus Therapeutics
FOLD
|
$47.8M |
| 2 |
RAPT Therapeutics
RAPT
|
$46.8M |
| 3 |
Scholar Rock
SRRK
|
$16.6M |
| 4 |
Cogent Biosciences
COGT
|
$12.7M |
| 5 |
Boston Scientific
BSX
|
$11.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Scholar Rock
SRRK
$3.14B
| $139M | 14.81% | 3,929,039 -469,242 | -11% | -$16.6M |
|
2
Krystal Biotech
KRYS
$4.27B
| $91.2M | 9.71% | 663,471 -74,204 | -10% | -$10.2M |
|
3
Zymeworks
ZYME
$1.12B
| $52.1M | 5.54% | 4,150,627 -638,318 | -13% | -$8.01M |
|
4
Stoke Therapeutics
STOK
$1.08B
| $49.7M | 5.29% | 4,375,931 -110,050 | -2% | -$1.25M |
|
5
Immunome
IMNM
$828M
| $45.3M | 4.82% | 4,872,225 -488,962 | -9% | -$4.55M |
|
6
Replimune Group
REPL
$422M
| $43.3M | 4.61% | 4,664,791 -233,736 | -5% | -$2.17M |
|
7
Nurix Therapeutics
NRIX
$714M
| $42.5M | 4.53% | 3,732,888 -319,039 | -8% | -$3.63M |
|
8
LivaNova
LIVN
$3.08B
| $42.1M | 4.48% | 934,271 -79,868 | -8% | -$3.6M |
|
9
ADC Therapeutics
ADCT
$345M
| $42M | 4.47% | 15,666,731 | – | – |
|
10
Akero Therapeutics
AKRO
$3.74B
| $41.3M | 4.4% | 774,311 -164,966 | -18% | -$8.8M |
|
11
Regenxbio
RGNX
$451M
| $39.2M | 4.17% | 4,775,717 -19,063 | -0.4% | -$157K |
|
12
Kymera Therapeutics
KYMR
$2.95B
| $35.1M | 3.73% | 803,289 -180,124 | -18% | -$7.86M |
|
13
Beam Therapeutics
BEAM
$1.66B
| $24.2M | 2.58% | 1,423,411 -186,918 | -12% | -$3.18M |
|
14
Absci
ABSI
$357M
| $21.2M | 2.26% | 8,253,316 | – | – |
|
15
Neurogene
NGNE
$264M
| $19.1M | 2.03% | 1,276,676 -31,387 | -2% | -$469K |
|
|
HNGE
16
Hinge Health, Inc.
HNGE
$4.4B
| $15.5M | 1.65% | +300,000 | New | +$15.5M |
|
17
89bio
ETNB
$1.34B
| $15.2M | 1.62% | 1,545,208 -341,236 | -18% | -$3.35M |
|
18
Annexon
ANNX
$226M
| $15.1M | 1.61% | 6,300,644 | – | – |
|
19
Fate Therapeutics
FATE
$120M
| $14.4M | 1.53% | 12,872,946 | – | – |
|
|
SLN
20
Silence Therapeutics
SLN
$227M
| $12.6M | 1.34% | 2,164,777 -50,170 | -2% | -$291K |
|
|
21
Cogent Biosciences
COGT
$1.69B
| $10.4M | 1.11% | 1,448,040 -1,767,986 | -55% | -$12.7M |
|
22
Biohaven
BHVN
$1.63B
| $10.3M | 1.1% | 729,515 -137,939 | -16% | -$1.95M |
|
23
Solid Biosciences
SLDB
$427M
| $9.33M | 0.99% | 1,915,926 -103,245 | -5% | -$503K |
|
|
24
Boston Scientific
BSX
$156B
| $9.16M | 0.98% | 85,301 -107,982 | -56% | -$11.6M |
|
25
IDEAYA Biosciences
IDYA
$2.15B
| $9.09M | 0.97% | 432,494 -102,106 | -19% | -$2.15M |
|